Carfilzomib Evidence Guide
Carfilzomib (Kyprolis) is FDA-approved for relapsed/refractory multiple myeloma with multiple Phase 3 trials (ASPIRE, ENDEAVOR) showing significant PFS improvement. As an irreversible proteasome inhibitor, it is active against bortezomib-resistant disease and is a standard component of modern myeloma combination regimens. A well-validated oncology drug with robust Phase 3 data.
Our Take
Carfilzomib (Kyprolis) is FDA-approved for relapsed/refractory multiple myeloma with multiple Phase 3 trials (ASPIRE, ENDEAVOR) showing significant PFS improvement. As an irreversible proteasome inhibitor, it is active against bortezomib-resistant disease and is a standard component of modern myeloma combination regimens. A well-validated oncology drug with robust Phase 3 data.
- Evidence context
- Relapsed/refractory multiple myeloma, proteasome inhibitor pharmacology, bortezomib-resistant disease
- Evidence grade
- Level A
- Confidence
- High
- Reference context
- Regulatory label reference: 20mg/m² IV on days 1 and 2 of cycle 1, then 27mg/m² (ASPIRE/ENDEAVOR dosing)
Benefits and Evidence
- Multiple Myeloma Response: Level A, includes human evidence - Phase 3 ASPIRE trial demonstrated superior progression-free survival when combined with lenalidomide and dexamethasone vs. lenalidomide and dexamethasone alone in relapsed myeloma.
- Overall Survival Benefit: Level A, includes human evidence - ENDEAVOR trial showed superior overall survival compared to bortezomib in relapsed or refractory multiple myeloma patients.
- Cardiac Toxicity Risk: Level A, includes human evidence - Cardiovascular adverse events including heart failure and cardiac arrest reported in clinical trials. Requires cardiac monitoring.
Side Effects and Warnings
- Fatigue
- Anemia and thrombocytopenia
- Dyspnea
- Hypertension
- Cardiac events (heart failure, arrhythmias)
- Peripheral neuropathy (less than bortezomib)
- Cardiac toxicity - assess cardiac function before and during treatment
- Pulmonary toxicity including ARDS reported
Research Dosage References
- <strong>Intravenous infusion</strong> - 20-56 mg/m2 - Days 1, 2, 8, 9, 15, 16 of 28-day cycle - Cycle 1 starts at 20 mg/m2 on days 1-2, then escalates to 27 or 56 mg/m2 based on regimen. Infuse over 10-30 minutes.
- <strong>Intravenous infusion</strong> - 70 mg/m2 (once-weekly) - Days 1, 8, 15 of 28-day cycle - Once-weekly dosing approved for convenience. Requires prehydration.
Mechanism of Action
Carfilzomib exerts anti-tumor effects through irreversible proteasome inhibition: 1. Irreversible 20S proteasome binding: Covalently binds to the chymotrypsin-like subunit (beta-5) of the 20S proteasome, providing sustained inhibition. 2. Protein homeostasis disruption: Prevents degradation of ubiquitinated proteins, leading to accumulation of misfolded proteins and endoplasmic reticulum stress. 3. NF-kB pathway inhibition: Blocks degradation of IkB, preventing activation of the pro-survival NF-kB signaling pathway. 4. Apoptosis induction: Triggers caspase-dependent apoptosis in myeloma cells through activation of intrinsic and extrinsic apoptotic pathways.
Legal Status
FDA-approved for relapsed or refractory multiple myeloma. Available by prescription only. Administered in healthcare settings. Marketed as Kyprolis by Amgen.
Primary Sources
- Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma (ASPIRE). N Engl J Med, 2015.
- Carfilzomib vs bortezomib in relapsed or refractory myeloma (ENDEAVOR). Lancet Oncol, 2016.
- Cardiovascular adverse events in carfilzomib-treated patients. Blood, 2019.
Quick Answers
Where is the strongest evidence for Carfilzomib?
Carfilzomib (Kyprolis) is FDA-approved for relapsed/refractory multiple myeloma with multiple Phase 3 trials (ASPIRE, ENDEAVOR) showing significant PFS improvement. As an irreversible proteasome inhibitor, it is active against bortezomib-resistant disease and is a standard component of modern myeloma combination regimens. A well-validated oncology drug with robust Phase 3 data. Evidence context: Relapsed/refractory multiple myeloma, proteasome inhibitor pharmacology, bortezomib-resistant disease.
What are the main side effects of Carfilzomib?
Carfilzomib side effects and warning signals include Fatigue, Anemia and thrombocytopenia, Dyspnea, Hypertension, and Cardiac events (heart failure, arrhythmias).
What evidence level is Carfilzomib?
Carfilzomib is rated Level A; the listed research status is FDA Approved.